IGF2BP1 promotes gastric cancer progression by stabilizing HS6ST2 mRNA in an N6-methyladenosine-dependent manner

Figure 5 Insulin-like growth factor 2 mRNA-binding protein 1 promotes the malignant phenotype of gastric cancer cells by regulating heparan sulfate 6-O-sulfotransferase 2. A and B: Western blot (A) and quantitative reverse-transcription polymerase chain reaction (B) for the expression levels of insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) and heparan sulfate 6-O-sulfotransferase 2 (HS6ST2) in SGC7901 cells after IGF2BP1 overexpression with or without HS6ST2 knockdown; C and D: Transwell (C) and wound healing (D) for the invasion and migration abilities of SGC7901 cells; E: Cell counting kit-8 assay for the proliferation ability of SGC7901 cells; F and G: Western blot (F) and quantitative reverse-transcription polymerase chain reaction (G) for the expression levels of IGF2BP1 and HS6ST2 in MGC803 cells after IGF2BP1 knockdown with or without HS6ST2 overexpression; H and I: Transwell (H) and wound healing (I) for the invasion and migration abilities of MGC803 cells; J: Cell counting kit-8 assay for the proliferation ability of MGC803 cells. Data are expressed as mean ± SD. ^aP < 0.05, ^bP < 0.01, ^cP < 0.001. IGF2BP: Insulin-like growth factor 2 mRNA-binding protein; HS6ST2: Heparan sulfate 6-O-sulfotransferase 2; shRNA: Short hairpin RNA; NC: Negative control; GAPDH: Gyceraldehyde-3-phosphate dehydrogenase; CCK-8: Cell counting kit-8.